Cardiovascular Disease Drug Development

提供解决方案使Real®用于心血管疾病。

  • Obtain cardiovascular endpoints earlier using preclinical models

  • Successfully execute complex mega-trials with Xcellerate®, the world's largest clinical trials knowledgebase

  • Partner with a company that has conducted more than 350 global studies with over 200,000 patients during the past five years

Covance偏好中心
Your Needs

跳动心血管疾病需要战略,科学的方法。从追踪变化的疾病模式,以发展疾病管理的尖端方法,这并不容易。这就是为什么你需要一个值得信赖的合作伙伴,他们跟上了快速发展的市场,并且具有丰富的小分子,基于装置的治疗和生物学的经验。在Covance,我们的专用心血管专家具有学术和行业经验的独特组合,为您提供了富有洞察力的学习设计,预测性研究管理和卓越运营服务。

The primary reason for late stage drug failure in cardiovascular trials is the inability to document improvement in outcomes. Therefore, we begin working with you as early as the preclinical phase to design outcomes oriented programs that help minimize risk and maximize your chance for success.

  • 早先通过我们的非卷轴心血管安全评估技术获得安全性,并获得“GO / NO-GO”决定的关键信息

  • 通过我们的心脏超声波,磁共振成像,核扫描和CT血管造影的经验增加了您的研究,通过利用目前服务的医生团队或已经服务于学术和核心影像实验室董事

  • Validate your drug’s safety and efficacy by proactively identifying those biomarkers – assays, multicomponent panels or imaging-based – that are most predictive of risk or success

  • Go beyond surrogate biomarkers by demonstrating actual improvements in cardiovascular outcomes with well-designed trials

  • Reach your clinical development goals faster with specialized design and conduct of Phase I - Phase IV trials across a wide range of small, molecule, devices and biologics including genetic therapies, peptides, enzyme replacement and stem cells

导航cardiovasc的特定的复杂性ular mega-trials is a big challenge. Success often depends on investigator interest and recruitment of appropriate patient populations. To help point you toward success, we have partnered with cardiovascular academic research organizations (AROs) who provide both medical and scientific leadership as well as insight into investigator and site quality. This partnership, in combination with Covance’s proprietary Xcellerate® knowledgebase—the world’s largest database of site selection and clinical laboratory data—enables you to identify patients for your trial faster, saving valuable time and money.

Once your trial is up and running, we will help to further reduce your timelines through proven operational efficiencies learned from prior successes in more than 200 global clinical endpoint trials.

Our Integrated Services

We deliver a holistic suite of services for cardiovascular drug development. From lead optimization through commercialization, we have the expertise and resources to help manage the complexity of your molecule and transform your results.

符合我们的专家

If you have a question for one of our cardiology experts, please click the button below.

Cheerag-Shirodaria-WEB

Charmag Shirodaria,MD,MBA
副总裁兼心血管全球治疗区
Honorary Consultant Cardiologist Oxford University Hospitals NHS Foundation Trust

Dr. Cheerag Shirodaria joined Covance in 2011 and has pursued clinical cardiology and intensive cardiac care in an Oxford University academic practice for more than a decade. As an interventional cardiologist, he provides expertise at Covance in all aspects of coronary artery disease, in particular acute coronary syndrome (ACS) and device therapies. He is also an expert in cardiac imaging, having completed his doctoral thesis on the use of novel MRI-based imaging techniques to assess vascular function.

Dr. Shirodaria also serves as the co-director of the cardiac CT imaging program at the University of Oxford, where he remains on the faculty. He has successfully designed and led a number of stem cell trials in the acute MI population and is a member of the trial steering committee for numerous trials.

Jonathan-Plehn-WEB

Jonathan Plehn,MD, FACC
副总裁、心血管药
医学临床教授,Drexel大学医学院

乔纳森博士在2008年在学术医疗实践和研究中,2008年搬到了NIH全国心脏,肺和血液研究所(NHLBI)的翻译医学分支的科学博士。Plehn的研究重点博士一直处于心力衰竭,肺动脉高压和血管疾病。他在乔治华盛顿大学,国家海军医疗中心和NHLBI定向了心力衰竭计划。他是NIH培训的心脏MRI,并指导了几个学术心脏超声临床和核心实验室,包括在Framingham心脏研究中建立了第一家二维回声实验室。

Dr. Plehn has participated as both an investigator and as a manager of a wide range of clinical trials. These have ranged from small proof of concept trials in rare diseases and novel molecules and biologics to phase 3 pivotal cardioavascular outcomes trials. At the same time he maintains his academic contacts continuing to publish and review manuscripts from top cardiology journals and is on the Editorial Board of the Journal of Cardiac Failure.